Rowland Charles A Jr

SEC source: 0001104659-26-012196 · tm265471-11_4seq1.xml · derivative · entry 8

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,000 shares

Expires not disclosed

F4 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.

F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.

SEC source: 0001104659-26-012196 · tm265471-11_4seq1.xml · derivative · entry 7

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,500 shares

Expires not disclosed

F4 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.

F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.

SEC source: 0001104659-26-012196 · tm265471-11_4seq1.xml · derivative · entry 6

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,920 shares

Expires not disclosed

F4 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.

F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.

SEC source: 0001104659-26-012196 · tm265471-11_4seq1.xml · derivative · entry 5

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,500 shares

Expires not disclosed

F4 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.

F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.

SEC source: 0001104659-26-012196 · tm265471-11_4seq1.xml · derivative · entry 4

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,200 shares

Expires not disclosed

F4 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.

F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.

SEC source: 0001104659-26-012196 · tm265471-11_4seq1.xml · derivative · entry 3

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,246 shares

Expires not disclosed

F4 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.

F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.

SEC source: 0001104659-26-012196 · tm265471-11_4seq1.xml · derivative · entry 2

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,000 shares

Expires not disclosed

F3 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an "In-The-Money Option"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time.

F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an "In-The-Money Option"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time.

F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an "In-The-Money Option"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time.

SEC source: 0001104659-26-012196 · tm265471-11_4seq1.xml · nonDerivative · entry 1

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"),

F2 · kind: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.

F1 · price: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"),

F2 · price: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.

SEC source: 0001193125-26-003110 · ownership.xml · derivative · entry 2

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,400

Underlying: Common Stock · 20,400 shares

Expires 2036-01-02

SEC source: 0001193125-26-003110 · ownership.xml · nonDerivative · entry 1

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,150

F1 · shares: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. All shares subject to the RSU shall vest on the one year anniversary of the grant date of the award.

SEC source: 0001193125-25-254300 · ownership.xml · derivative · entry 7

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 22,000 shares

Expires 2032-01-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001193125-25-254300 · ownership.xml · derivative · entry 6

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 22,000 shares

Expires 2031-01-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001193125-25-254300 · ownership.xml · derivative · entry 5

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,000 shares

Expires 2028-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001193125-25-254300 · ownership.xml · nonDerivative · entry 4

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.02 to $35.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001193125-25-254300 · ownership.xml · nonDerivative · entry 3

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,000

SEC source: 0001193125-25-254300 · ownership.xml · nonDerivative · entry 2

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,000

SEC source: 0001193125-25-254300 · ownership.xml · nonDerivative · entry 1

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,000

SEC source: 0001415889-25-015960 · form4-06062025_040611.xml · derivative · entry 1

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2035-06-03

F1 · derivative.exercise_date: This option was granted on June 4, 2025. The shares underlying the option will fully vest on the earlier of: June 4, 2026 and the date of Generation Bio's 2026 annual meeting of stockholders.

SEC source: 0000950170-25-002482 · ownership.xml · derivative · entry 1

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,800

Underlying: Common Stock · 18,800 shares

Expires 2035-01-02

SEC source: 0001415889-24-016185 · form4-06102024_040617.xml · derivative · entry 1

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2034-06-05

F1 · derivative.exercise_date: This option was granted on June 6, 2024. The shares underlying the option will fully vest on the earlier of: June 6, 2025 and the date of Generation Bio's 2025 annual meeting of stockholders.

SEC source: 0000950170-24-007074 · ownership.xml · derivative · entry 3

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 105,000 shares

Expires 2033-06-13

F2 · kind: On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company ("KKC") acquired all outstanding Ordinary Shares of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"). At the effective time of the Scheme of Arrangement, each outstanding Ordinary Share of the Company was exchanged for an amount equal to (a) $1.60 in cash, without interest (the "Cash Consideration"), and (b) one contractual contingent value right (each, a "CVR"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC.

F3 · kind: (continued) In addition, each ADS of the Company was exchanged for an amount equal to (a) $16.00 in cash (less certain Orchard ADS Fees pursuant to the terms of the deposit agreement, dated as of November 2, 2018, as amended, by and among the Company, Citibank, N.A., as depositary, and all holders and beneficial owners of Orchard ADSs issued thereunder), and (b) 10 CVRs. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023.

F4 · derivative.exercise_date: Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR.

F1 · derivative.underlying: The ordinary shares, nominal value GBP 0.10 per share (the "Ordinary Shares") may be represented by American Depositary Shares ("ADSs"), each of which currently represents ten Ordinary Shares.

SEC source: 0000950170-24-007074 · ownership.xml · derivative · entry 2

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 46,000 shares

Expires 2032-06-06

F2 · kind: On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company ("KKC") acquired all outstanding Ordinary Shares of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"). At the effective time of the Scheme of Arrangement, each outstanding Ordinary Share of the Company was exchanged for an amount equal to (a) $1.60 in cash, without interest (the "Cash Consideration"), and (b) one contractual contingent value right (each, a "CVR"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC.

F3 · kind: (continued) In addition, each ADS of the Company was exchanged for an amount equal to (a) $16.00 in cash (less certain Orchard ADS Fees pursuant to the terms of the deposit agreement, dated as of November 2, 2018, as amended, by and among the Company, Citibank, N.A., as depositary, and all holders and beneficial owners of Orchard ADSs issued thereunder), and (b) 10 CVRs. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023.

F4 · derivative.exercise_date: Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR.

F1 · derivative.underlying: The ordinary shares, nominal value GBP 0.10 per share (the "Ordinary Shares") may be represented by American Depositary Shares ("ADSs"), each of which currently represents ten Ordinary Shares.

SEC source: 0000950170-24-007074 · ownership.xml · nonDerivative · entry 1

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · security: The ordinary shares, nominal value GBP 0.10 per share (the "Ordinary Shares") may be represented by American Depositary Shares ("ADSs"), each of which currently represents ten Ordinary Shares.

F2 · kind: On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company ("KKC") acquired all outstanding Ordinary Shares of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"). At the effective time of the Scheme of Arrangement, each outstanding Ordinary Share of the Company was exchanged for an amount equal to (a) $1.60 in cash, without interest (the "Cash Consideration"), and (b) one contractual contingent value right (each, a "CVR"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC.

F3 · kind: (continued) In addition, each ADS of the Company was exchanged for an amount equal to (a) $16.00 in cash (less certain Orchard ADS Fees pursuant to the terms of the deposit agreement, dated as of November 2, 2018, as amended, by and among the Company, Citibank, N.A., as depositary, and all holders and beneficial owners of Orchard ADSs issued thereunder), and (b) 10 CVRs. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023.

F2 · price: On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company ("KKC") acquired all outstanding Ordinary Shares of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"). At the effective time of the Scheme of Arrangement, each outstanding Ordinary Share of the Company was exchanged for an amount equal to (a) $1.60 in cash, without interest (the "Cash Consideration"), and (b) one contractual contingent value right (each, a "CVR"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC.

F3 · price: (continued) In addition, each ADS of the Company was exchanged for an amount equal to (a) $16.00 in cash (less certain Orchard ADS Fees pursuant to the terms of the deposit agreement, dated as of November 2, 2018, as amended, by and among the Company, Citibank, N.A., as depositary, and all holders and beneficial owners of Orchard ADSs issued thereunder), and (b) 10 CVRs. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023.

SEC source: 0001209191-24-000924 · doc4.xml · derivative · entry 1

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,000

Underlying: Common Stock · 32,000 shares

Expires 2034-01-02

SEC source: 0001415889-23-015864 · form4-12052023_041219.xml · nonDerivative · entry 2

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 534,757

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.34 to $1.55, inclusive.

SEC source: 0001415889-23-015864 · form4-12052023_041219.xml · nonDerivative · entry 1

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 384,757

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.13 to $1.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) and (3) of this Form 4.

SEC source: 0001209191-23-037904 · doc4.xml · derivative · entry 1

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,000

Underlying: Ordinary Shares · 105,000 shares

Expires 2033-06-13

F1 · derivative.exercise_date: All of the shares subject to this option vest upon the earlier to occur of June 14, 2024 or the date of the 2024 Annual General Meeting of the Company.

F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents ten Ordinary Shares.

SEC source: 0001415889-23-009611 · form4-06122023_040618.xml · derivative · entry 1

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2033-06-07

F1 · derivative.exercise_date: This option was granted on June 8, 2023. The shares underlying the option will fully vest on the earlier of: June 8, 2024 and the date of Generation Bio's 2024 annual meeting of stockholders.

SEC source: 0001209191-23-030796 · doc4.xml · derivative · entry 3

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 40,000 shares

Expires 2027-07-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0001209191-23-030796 · doc4.xml · nonDerivative · entry 2

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0001209191-23-030796 · doc4.xml · nonDerivative · entry 1

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0001209191-23-001313 · doc4.xml · derivative · entry 1

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2033-01-03

SEC source: 0001415889-22-009796 · form4-09202022_010937.xml · nonDerivative · entry 1

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 191,797

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.14 to $5.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001415889-22-009776 · form4-09192022_020903.xml · nonDerivative · entry 2

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 176,047

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.29 to $5.73, inclusive.

SEC source: 0001415889-22-009776 · form4-09192022_020903.xml · nonDerivative · entry 1

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 142,566

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.24 to $5.53, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) through (2) of this Form 4.

SEC source: 0001415889-22-009671 · form4-09152022_010903.xml · nonDerivative · entry 2

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,419

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.10 to $5.40, inclusive.

SEC source: 0001415889-22-009671 · form4-09152022_010903.xml · nonDerivative · entry 1

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 119,819

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.08 to $5.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) of this Form 4.

SEC source: 0001104659-22-085790 · tm2222534-5_4seq1.xml · nonDerivative · entry 1

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,277

SEC source: 0001415889-22-006477 · form4-06132022_040612.xml · derivative · entry 1

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,200

Underlying: Common Stock · 19,200 shares

Expires 2032-06-08

F1 · derivative.exercise_date: This option was granted on June 9, 2022. The shares underlying the option will fully vest on the earlier of: June 9, 2023 and the date of Generation Bio's 2023 annual meeting of stockholders.

SEC source: 0001209191-22-035007 · doc4.xml · derivative · entry 1

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,000

Underlying: Ordinary Shares · 46,000 shares

Expires 2032-06-06

F1 · derivative.exercise_date: All of the shares subject to this option vest upon the earlier to occur of June 7, 2023 or the date of the 2023 Annual General Meeting of the Company.

F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

SEC source: 0001209191-22-001983 · doc4.xml · derivative · entry 1

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2032-01-03

SEC source: 0001104659-21-100288 · tm2123911-5_4seq1.xml · nonDerivative · entry 1

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,773

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.20 to $1.205, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-21-098427 · tm2123737-6_4seq1.xml · derivative · entry 2

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Ordinary Shares · 35,000 shares

Expires 2031-07-28

F3 · date: The option was granted on July 28, 2021.

F4 · derivative.exercise_date: One hundred percent (100%) of the option will vest on July 31, 2022, subject to the reporting person's continued service on the board of directors of Nabriva Therapeutics plc.

SEC source: 0001104659-21-098427 · tm2123737-6_4seq1.xml · nonDerivative · entry 1

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,550

F1 · balance_after: The reported transaction involved the reporting person's receipt of a grant of 17,500 restricted stock units. The total reported in Column 5 includes the 17,500 newly awarded restricted stock units.

F2 · balance_after: The number of ordinary shares reported on this Form 4 reflects a 1-for-10 reverse stock split effected on December 3, 2020.

SEC source: 0001209191-21-041507 · doc4.xml · derivative · entry 1

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Ordinary Shares · 40,000 shares

Expires 2031-06-15

F1 · derivative.exercise_date: All of the shares subject to this option vest upon the earlier to occur of June 16, 2022 or the date of the 2022 Annual General Meeting of the Company.

F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

SEC source: 0001415889-21-002951 · form4-06112021_010625.xml · derivative · entry 1

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2031-06-08

F1 · derivative.exercise_date: This option was granted on June 9, 2021. The shares underlying the option will fully vest on the earlier of: June 9, 2022 and the date of Generation Bio's 2022 annual meeting of stockholders.

SEC source: 0001179110-21-006417 · edgar.xml · derivative · entry 2

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,500

Underlying: Common Stock · 4,500 shares

Expires 2031-06-02

F2 · derivative.exercise_date: This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 2, 2022.

SEC source: 0001179110-21-006417 · edgar.xml · nonDerivative · entry 1

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,812

F1 · kind: The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 2, 2022. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0001415889-21-000310 · form4-01132021_010126.xml · nonDerivative · entry 1

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,035

SEC source: 0001209191-21-002140 · doc4.xml · derivative · entry 1

Rowland Charles A Jr · CIK 0001383292 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2031-01-04